NCT05351593View on ClinicalTrials.gov

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

June 30, 2026

Conditions

CNS LymphomaPrimary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma

Interventions

DRUG

Tafasitamab

Given IV

DRUG

Lenalidomide

Given Orally

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

James Rubenstein

OTHER